AKBA

SEC source: 0001562180-19-003434 · primarydocument.xml · nonDerivative · entry 1

Enyedy Mark J · CIK 0001586965 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,443

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001562180-19-003338 · primarydocument.xml · derivative · entry 6

Butler John P. · CIK 0001591467 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 287,000 shares

Expires 2023-09-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: On September 16, 2013, the Issuer granted the reporting person an option to purchase 612,500 shares of the Issuer's common stock (the "Option") under the Issuer's Amended and Restated 2008 Equity Incentive Plan. 25% of the shares underlying the Option vested on the first anniversary of the grant date, and the remaining 75% vested in equal monthly installments over the following three years. Prior to May 31, 2019, the reporting person exercised the Option with respect to 325,500 shares. On May 31, 2019, the reporting person exercised the Option with respect to 287,000 shares, as reported on this Form 4.

SEC source: 0001562180-19-003338 · primarydocument.xml · nonDerivative · entry 1

Butler John P. · CIK 0001591467 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 836,232

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Reflects the transfer on March 15, 2019 of 65,150 shares of common stock from the reporting person's direct holdings to certain of the reporting person's trusts, the holdings for which are reported in Table I of this Form 4.

SEC source: 0001562180-19-003224 · primarydocument.xml · derivative · entry 2

Faulkingham Dell · CIK 0001776024 · CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2029-05-31

F2 · derivative.exercise_date: The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with Akebia in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0001562180-19-003224 · primarydocument.xml · nonDerivative · entry 1

Faulkingham Dell · CIK 0001776024 · CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 100% of the restricted stock units will vest on the first anniversary of the grant date.

SEC source: 0000899243-19-010590 · doc4.xml · nonDerivative · entry 1

Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,932

F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units.

SEC source: 0000899243-19-010587 · doc4.xml · nonDerivative · entry 1

Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,618

F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units.

SEC source: 0000899243-19-010591 · doc4.xml · nonDerivative · entry 1

Jain Rita · CIK 0001707797 · SVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,332

F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units.

SEC source: 0000899243-19-010589 · doc4.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, CLO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,806

F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units.

SEC source: 0000899243-19-010588 · doc4.xml · nonDerivative · entry 1

Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,324

F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units.

SEC source: 0001562180-19-001677 · primarydocument.xml · derivative · entry 2

Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-02-28

F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0001562180-19-001677 · primarydocument.xml · nonDerivative · entry 1

Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,841

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.

SEC source: 0001562180-19-001675 · primarydocument.xml · derivative · entry 2

Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-02-28

F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0001562180-19-001675 · primarydocument.xml · nonDerivative · entry 1

Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,766

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.

F2 · balance_after: Includes 265 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018.

SEC source: 0001562180-19-001680 · primarydocument.xml · derivative · entry 2

Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2029-02-28

F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0001562180-19-001680 · primarydocument.xml · nonDerivative · entry 1

Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,399

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.

F2 · balance_after: Includes 1,170 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018.

SEC source: 0001562180-19-001679 · primarydocument.xml · derivative · entry 2

Jain Rita · CIK 0001707797 · SVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 115,000 shares

Expires 2029-02-28

F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0001562180-19-001679 · primarydocument.xml · nonDerivative · entry 1

Jain Rita · CIK 0001707797 · SVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,741

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.

SEC source: 0001562180-19-001676 · primarydocument.xml · derivative · entry 2

Hadas Nicole R. · CIK 0001602396 · SVP, CLO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-02-28

F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0001562180-19-001676 · primarydocument.xml · nonDerivative · entry 1

Hadas Nicole R. · CIK 0001602396 · SVP, CLO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,735

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.

F2 · balance_after: Includes 451 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018.

SEC source: 0001562180-19-001674 · primarydocument.xml · derivative · entry 6

Butler John P. · CIK 0001591467 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2029-02-28

F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0001562180-19-001674 · primarydocument.xml · nonDerivative · entry 1

Butler John P. · CIK 0001591467 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 614,382

F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.

F2 · balance_after: Includes 265 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018.

SEC source: 0000899243-18-030793 · doc4.xml · nonDerivative · entry 1

Dahan Michel · CIK 0001669737 · SVP, Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,841

F1 · balance_after: Includes 2,000 shares of common stock inadvertently omitted from the reporting person's Form 3 filed on March 18, 2016.

SEC source: 0000899243-18-030952 · doc4.xml · derivative · entry 5

Morrison Jodie Pope · CIK 0001618247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-12-12

F4 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0000899243-18-030952 · doc4.xml · derivative · entry 4

Morrison Jodie Pope · CIK 0001618247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2028-06-30

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030952 · doc4.xml · derivative · entry 3

Morrison Jodie Pope · CIK 0001618247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2027-06-09

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030952 · doc4.xml · derivative · entry 2

Morrison Jodie Pope · CIK 0001618247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,716

Underlying: Common Stock · 18,716 shares

Expires 2026-06-21

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030952 · doc4.xml · nonDerivative · entry 1

Morrison Jodie Pope · CIK 0001618247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,919

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the "Merger Agreement"), each share of common stock of Keryx Biopharmaceuticals, Inc. ("Keryx") owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time") was automatically converted into 0.37433 shares of the Issuer's common stock (the "Exchange Multiplier").

SEC source: 0000899243-18-030789 · doc4.xml · nonDerivative · entry 1

Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,501

F1 · balance_after: Includes 1,500 shares acquired under the Akebia Therapeutics, Inc. stock purchase plan on June 29, 2018.

SEC source: 0000899243-18-030945 · doc4.xml · derivative · entry 5

Heffernan Michael Thomas · CIK 0001448914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-12-12

F4 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0000899243-18-030945 · doc4.xml · derivative · entry 4

Heffernan Michael Thomas · CIK 0001448914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2028-06-30

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030945 · doc4.xml · derivative · entry 3

Heffernan Michael Thomas · CIK 0001448914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2027-06-09

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030945 · doc4.xml · derivative · entry 2

Heffernan Michael Thomas · CIK 0001448914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,716

Underlying: Common Stock · 18,716 shares

Expires 2026-06-21

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030945 · doc4.xml · nonDerivative · entry 1

Heffernan Michael Thomas · CIK 0001448914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,486

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the "Merger Agreement"), each share of common stock of Keryx Biopharmaceuticals, Inc. ("Keryx") owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time") was automatically converted into 0.37433 shares of the Issuer's common stock (the "Exchange Multiplier").

SEC source: 0000899243-18-030946 · doc4.xml · derivative · entry 1

ADAMS ADRIAN · CIK 0001248144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-12-12

F1 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0000899243-18-030951 · doc4.xml · derivative · entry 6

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-12-12

F4 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0000899243-18-030951 · doc4.xml · derivative · entry 5

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2028-06-30

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030951 · doc4.xml · derivative · entry 4

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2027-06-09

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030951 · doc4.xml · derivative · entry 3

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2026-05-26

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030951 · doc4.xml · derivative · entry 2

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,716

Underlying: Common Stock · 18,716 shares

Expires 2026-03-31

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030951 · doc4.xml · nonDerivative · entry 1

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the "Merger Agreement"), each share of common stock of Keryx Biopharmaceuticals, Inc. ("Keryx") owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time") was automatically converted into 0.37433 shares of the Issuer's common stock (the "Exchange Multiplier").

SEC source: 0000899243-18-030948 · doc4.xml · derivative · entry 6

GILMAN STEVEN C · CIK 0001379970 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-12-12

F4 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0000899243-18-030948 · doc4.xml · derivative · entry 5

GILMAN STEVEN C · CIK 0001379970 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2028-06-30

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030948 · doc4.xml · derivative · entry 4

GILMAN STEVEN C · CIK 0001379970 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2027-06-09

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030948 · doc4.xml · derivative · entry 3

GILMAN STEVEN C · CIK 0001379970 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2026-05-26

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030948 · doc4.xml · derivative · entry 2

GILMAN STEVEN C · CIK 0001379970 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,716

Underlying: Common Stock · 18,716 shares

Expires 2026-03-31

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030948 · doc4.xml · nonDerivative · entry 1

GILMAN STEVEN C · CIK 0001379970 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,231

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the "Merger Agreement"), each share of common stock of Keryx Biopharmaceuticals, Inc. ("Keryx") owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time") was automatically converted into 0.37433 shares of the Issuer's common stock (the "Exchange Multiplier").

SEC source: 0000899243-18-030947 · doc4.xml · derivative · entry 4

Enyedy Mark J · CIK 0001586965 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-12-12

F4 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.

SEC source: 0000899243-18-030947 · doc4.xml · derivative · entry 3

Enyedy Mark J · CIK 0001586965 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,229

Underlying: Common Stock · 11,229 shares

Expires 2028-06-30

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.

SEC source: 0000899243-18-030947 · doc4.xml · derivative · entry 2

Enyedy Mark J · CIK 0001586965 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,716

Underlying: Common Stock · 18,716 shares

Expires 2027-09-11

F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent.

F2 · derivative.exercise_date: The option is fully vested and currently exercisable.